info@seagull-health.com
SeagullHealth
search
zolbetuximab(Vyloy)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Vyloy(zolbetuximab) Instructions:Uses,Dosage, Side Effects
Zolbetuximab is an IgG1 monoclonal antibody targeting Claudin 18.2 (CLDN18.2), which has shown significant therapeutic potential in the treatment of CLDN18.2-positive advanced or metastatic gastric cancer. When using zolbetuximab, understanding and following its correct administration method and dosage is also important for ensuring therapeutic efficacy.
VYLOY is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.
When used in combination with other antineoplastic therapeutic agents, the recommended first dose for adult patients is 800 mg/m², and the dose from the second administration onwards may be reduced to 600 mg/m².
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
